LipoScience, a provider of a proprietary test for assessing the risk of heart disease, announced the terms for its upcoming IPO on Thursday. The Raleigh, NC based company plans to offer 5 million shares at a range of $14-$16. Lead manager Merrill Lynch is expected to price this deal on Thursday, September 19.
